This trial is evaluating whether Supplement dose 7.5g/d will improve 4 primary outcomes and 6 secondary outcomes in patients with Metabolic Syndrome. Measurement will happen over the course of Change between the beginning and the end of the intervention (6 weeks).
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Supplement Dose 7.5g/d is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"The prevalence of MetS varies by population and sex and is estimated to occur in 18.7% of men and 15.3% of women. Of persons diagnosed with MetS, around 20.1% will progress to diabetes, heart disease or stroke." - Anonymous Online Contributor
"Metabolic syndrome (MS) and related disorders are characterized by many health problems and a high risk of death within the next decade. Patients with MS are usually not satisfied with the treatment and rarely follow up for long. The first choice of treatment is a healthy lifestyle, especially in patients with a family history of cardiovascular diseases. If this has not been implemented, then it is worthwhile to implement a structured diet with regular exercise and even use weight-loss drugs. The use of oral medications, such as niacin can help reduce triglyceride levels in MS patients. MS patients also need to have regular checks by the physician every three to four months. If necessary, the patient must have a discussion about their treatment at a later date." - Anonymous Online Contributor
"MetS is a complex ndependency on many causes that nturns into the pathophysiology of many ndiseases and that may be difficult to pinpoint. One such ndisease is type II diabetes." - Anonymous Online Contributor
"Metabolic syndrome can be partially healed to the degree that, in many instances, the metabolic and cardiovascular disease risk is reduced to that of a subjects with a healthy heart and normal blood cholesterol and blood pressure levels. We speculate that metabolic syndrome represents one component of the full MetS syndrome and that its major pathogenic components are (1) the increased production of pro-inflammatory cytokines by the adipose tissue; (2) the reduced bioavailability of nitric oxide (NO), a vasodilator and a potent anti-inflammatory mediator." - Anonymous Online Contributor
"Patients who develop MetS are characterized by a set of clinical and biological features that are consistent with a chronic inflammatory condition, and these features are independent of the severity of their metabolic syndrome. A substantial proportion of MetS patients have elevated circulating levels of markers of inflammation, suggesting that patients who develop MetS are particularly vulnerable to the deleterious effects of inflammation in the aging body. At present, there is no treatment for MetS, and we therefore propose that patients presenting to general practices with MetS should be referred to general practitioners who have experience in treating depression and other inflammatory conditions." - Anonymous Online Contributor
"The signs of metabolic syndrome may include central obesity (waist circumference >100 cm), hyperglycaemia (blood glucose >110 mg/dL), hypertriglyceridemia (triglyceride >150 mg/dL) and low HDL cholesterol (<35 mg/dL)." - Anonymous Online Contributor
"The current protocol for a supplement dosing of 7.5g/d is not associated with any significant changes in renal function at this dose. This dose may be feasible for use in clinical settings to help people overcome the restrictive effects of a low-protein diet." - Anonymous Online Contributor
"The lower limit of our results indicates that supplement with 7.5g/d DHA and EPA may be more effective than placebo for the treatment of metabolic syndrome." - Anonymous Online Contributor
"Individuals with MetS have a high risk of mortality attributable to a variety of cardiovascular disorders, a higher risk of cardiovascular disease, and an increased risk of mortality from diabetes and from cancer." - Anonymous Online Contributor
"We concluded the following: Supplement dose 7.5 g/d, compared to 5.0 g/d, increases both weight and waist circumference and decreases LDL-C levels, without affecting HDL-C, SBP, fasting glucose or insulin levels." - Anonymous Online Contributor
"We created predictive models for the selection of patients likely to be responsive to a given clinical trial. The models identified all patients who responded to the METS Trial according to a single endpoint. The odds of benefiting in a given patient in a clinical trial may vary considerably, and patient characteristics should be considered in evaluating trial results." - Anonymous Online Contributor
"If this supplement had no effect on cardiovascular risk factors, people might be advised to take less. These data would suggest a maximum dose of 5 mg/d." - Anonymous Online Contributor